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The effect of I-oleoyl-2-acetylgIy~ro1 (OAG) on the thrombin-endued rise in intracellular Ca2+ levels 
([Ca2+]J and 5-hydroxy~*~]tryptamine ([%]5HT) secretion was studied. In washed human platelets pre- 
labelled with fYJ5HT and quin 2, OAG (10-50 pg/mI) induced no significant aggregation, [Y]5HT secre- 
tion or rise in [Ca*+], in the presence or absence of fibrinogen. However, addition of OAG (IO-50 pg/mi) 
10 s to 5 min before or IO-60 s after addition of threshold concentrations of thrombin (co.03 U/ml) resulted 
in a significant potentiation of aggregation and [‘QHT secretion without any effect on the thrombin-in- 
duced rise in [Ca2+],. Both EGTA, which abolished the latter and creatine phosphate/creatine phospho- 
kinase, the ADP scavenger, totally inhibited the aggregation but only partially reduced [‘4C]5HT secretion 
in response to thrombin plus OAG. At higher concentrations of thrombin, neither the rise in [Caz+]l nor 
the extent of [Y]5HT secretion was significantly altered by OAG addition. The results demonstrate that, 
unlike phorbol esters, OAG has no inhibitory effect on thrpmbin-induced [Ca2+], mobilisation but can syn- 
ergize with low concentrations of thrombin in potentiating [%JSHT secretion even at basal [Ca”],. 
1. INTRODUCTION 
Recent studies have demonstrated that a number 
of agonist-induced receptor-mediated processes in 
different cell types can be inhibited by tumour- 
promoting phorbol esters, which exhibit protein 
kinase C-activating properties [l-7]. In platelets, it 
has been shown that phorbol esters such as phor- 
bol 12-myristate 13-acetate and phorbol 12,13-di- 
butyrate can inhibit phosphoinositide breakdown, 
intracellular Ca*+ ([Ca”]i) mobilisation and gran- 
ule secretion induced by agonists such as throm- 
bin, and platelet-activating factor [l-4]. These 
observations have led to the idea that protein 
kinase C activation may have a role to play in the 
termination of agonist-induced transduction pro- 
cesses, which lead to platelet activation [5]. 
The effects of phorbol esters on protein kinase 
C are mimicked by diacylglycerol (DAG) [8,9], 
which is formed endogenously upon agonist stimu- 
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lation in platelets, as well as in other cells [lO,ll] 
via the phosphodiesteratic leavage of the phos- 
phoinositides, particularly phosphatidylinositol 
4,5-bisphosphate (PtdIns-4,5P2). In intact plate- 
lets, only certain exogenously added diacyl- 
glycerols with optimum water and lipid solubility 
characteristics enabling them to partition effec- 
tively into the lipid bilayer have protein kinase C- 
activating properties, and these include I-oleoyl-2- 
acetylglycerol (OAG) and 1,2-didecanoylglycerol 
[12,13]. Although OAG and phorbol esters have 
similar stimulatory effects on platelet secretion and 
aggregation [8,14,15] because of their protein 
kinase C-activating properties, recent work sug- 
gests that certain basic differences between these 
compounds exist regarding their effect on the 
platelet adenylate cyclase system and the role of 
endogenously released ADP [16]. This study, 
which was aimed at further characterisation of the 
effects of OAG on platelets, demonstrates further 
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differences in the mechanism of action of phorbol 
esters and OAG. In our experiments, OAG had no 
inhibitory effect on the rise in [Ca”]i or 5-hy- 
droxytryptamine (5HT) secretion induced by 
thrombin, although at low thrombin concentra- 
tions and at basal [Ca’+]i, synergistic potentiation 
of 5HT secretion by OAG and thrombin was 
observed. 
2. EXPERIMENTAL 
Blood collection from apparently healthy human 
male volunteers, who had denied taking any medi- 
cation for at least 10 days, and preparation of 
platelet-rich plasma (PRP) were carried out as 
described [17]. Washed platelets were prepared by 
addition of 0.11 N citric acid and 30 nM PGI2 to 
PRP, followed by centrifugation of the PRP at 
1500 x g for 15 min. The platelet pellet was resus- 
pended in a pH6.5 buffer composed of 36mM 
citric acid, 5 mM KCl, 103 mM NaCl, 0.5 mM 
CaCl2 and 0.09% glucose. For studies on the mea- 
surement of 5HT release and [Ca2+]i, platelets re- 
suspended in this buffer were incubated with 
0.1 &i/ml of [ 14C] 5HT (50 Ci/mmol, Amersham) 
plus 5rM quin 2 acetoxymethyl ester (Amersham) 
or with 5yM quin 2 ester alone respectively, for 
30 min at 37°C in the presence of 0.05 U/ml hiru- 
din. Prior to centrifugation at 1500 x g for 10 min, 
30 nM PGI2 and 1 U/ml apyrase (grade V, Sigma) 
were added and following centrifugation, the plate- 
let pellet was resuspended in a pH 7.4 buffer com- 
posed of 10 mM Hepes, 103 mM NaCl, 5 mM KCl, 
1 mM MgS04, 1 mM CaC12 and 0.09% glucose at 
a platelet count of l-l.5 x lo8 or 2.5-3 x log/ml 
for the [Ca2+]i and [14C]5HT determinations, re- 
spectively. In some experiments, hirudin 
(0.05 U/ml) was added at the start of the experi- 
ment, but this did not significantly affect the re- 
sults obtained. 
OAG (Calbiochem), which was obtained as a 
solution dissolved in hexane, was dried down under 
N2 and re-dissolved in dried dimethyl sulphoxide 
(DMSO) as a 100 mg/ml solution. In all the experi- 
ments with OAG and thrombin, OAG or DMSO 
vehicle (0.04%) was added 10 s to 10 min before or 
10 s to 2 min after thrombin addition. Platelet 
aggregation was measured as the percentage in- 
crease in light transmission as in [ 171. For the 
[ 14C] 5HT experiments, incubations were termi- 
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nated 3 min after thrombin addition with EDTA 
(16 mM) plus formaldehyde (lOro), followed by 
rapid centrifugation of the samples and collection 
of the supernatants for 14C liquid scintillation 
counting. For the studies on [Ca’+]i determina- 
tions, fluorescence measurements were carried out 
in quin 2-loaded platelets incubated at 37°C in a 
Perkin Elmer LS-5 luminescence spectrometer. 
Calibration of the fluorescence signals and calcula- 
tion of [Ca’+]i (in nM) were carried out as de- 
scribed by Tsien et al. [18]. In some experiments, 
5 mM EGTA was added 2 min before addition of 
OAG and thrombin to enable [14C]5HT and 
[Ca2+]i determinations to be made in the absence 
of extracellular Ca’+. Statistical analysis of all the 
data was carried out using the Student’s t-test for 
unpaired data. 
3. RESULTS 
Addition of OAG (lo-50 pg/ml) to quin 
2/ [ 14C] SHT-labelled washed platelets in the pres- 
ence or absence of 0.5-l mg/ml fibrinogen 
(human, Kabi), resulted in no significant aggrega- 
tion (fig. l), [14C]5HT release or rise in [Ca’+]i 
(fig.2) compared with that in resting, unstimulated 
platelets. This was found to be the case even when 
OAG from another source (Nova Biochem) was 
tested (not shown). However, OAG (lo-50pg/ml) 
was able to potentiate significantly both the aggre- 
gation and [r4C]5HT secretion, when added 10 s to 
5 min before or lo-60 s after addition of sub- 
threshold to threshold concentrations of thrombin 
(0.01-0.03 U/ml), which induced little or no aggre- 
gation and [ 14C] 5HT release on their own (figs 1,2). 
The data in figs 1 and 2 are those obtained in indo- 
methacin-treated platelets, although the absence of 
indomethacin pre-treatment did not affect any of 
the results obtained (not shown). The small rise in 
[Ca’+]i induced by these concentrations of throm- 
bin, ranging between 100 and 200nM in the pres- 
ence of 1 mM external Ca2+, was not significantly 
affected (p > 0.05) by addition of OAG (fig.2). 
The potentiation of thrombin (0.01-0.03 U/ml)- 
induced [ 14C] 5HT secretion by OAG was still pres- 
ent in EGTA-treated platelets, in which no signifi- 
cant aggregation (not shown), [ 14C] 5HT secretion 
or rise in [Ca2+]r in response to thrombin alone was 
noted (fig.2). However, the extent of [14C]5HT 
release in response to OAG + thrombin was signifi- 
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Fig.1. Effect of OAG on threshold thrombin (0.02 U/ml)- 
induced human platelet aggregation in the presence of 
1 mM external Ca’+. Indomethacin (10pM) and imipra- 
mine (3rM) treated platelets pre-loaded with quin 2 were 
pre-incubated with vehicle or CP/CPK for 1 min at 
37°C prior to vehicle or OAG (25pg/ml) addition, fol- 
lowed 10s later by thrombin (T). Traces a-d represent 
vehicle + T, OAG + vehicle, OAG + T and CP/CPK + 
OAG + T, respectively. For trace b, fibrinogen 
(0.5-l mg/ml) was present. The traces shown are typical 
of 3 similar experiments using platelets from different 
donors. 
cantly (p < 0.005) smaller in EGTA-treated plate- 
lets (19.6 f 4.4%) than that obtained in the presence 
of 1 mM external Ca2+ (37.4 f 3.6%). Similarly, 
5 mM creatine phosphate (CP) plus 25 U/ml crea- 
tine phosphokinase (CPK), which abolished plate- 
let responses to 10,uM ADP (not shown), abolished 
the potentiation of thrombin-induced aggregation 
by OAG (fig.1) but only partially reduced the 
potentiation of [ 14C]5HT secretion by OAG (fig.2). 
The extent of [14C]5HT release in platelets treated 
with CP/CPK plus OAG (25ag/ml) plus thrombin 
was 10.6 + 2.4% and, while this was significantly 
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Fig.2. Effect of OAG on threshold thrombin (T) (0.02 U/ ml)-induced [Ca”], mobilisation and [14C]5HT release in quin 
2 and [14C]5HT-labelled platelets, in the presence of 1 mM external Ca2+ (upper) or 5 mM EGTA (lower). Platelets were 
pre-treated with indomethacin (1OrM) and imipramine (3cM). Traces a-d are as described in the legend to fig. 1 while 
trace e represents the addition of OAG 5 min before thrombin. The values in parentheses beside each trace denote the 
percentage [r4C]5HT released into the platelet supernatants and represent he means f SE of 9-12 determinations from 
3 different donors. The fluorescence traces are representative ones from the same number of experiments. The [Ca”], 
calibration scale is shown along the vertical axis on the left. 
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Table 1 
Effect of OAG on high-dose thromb~n-induced rise in 
[Ca2+], and [%]5HT secretion i  the presence of 1 mM 
external Ca’+ 
[Ca2”], % ji4C]5HT 
(nM) release 
Resting 84& 3 0 
Vehicle + 0.2 U/ml thrombin 772 f 177 72 f 3 
OAG + 0.2 U/ml thrombin 596 -e 145 71 zt3 
CP/CPK + OAG + 0.2 U/ml 
thrombin 610 rt 115 68 + 1.5 
Vehicle or OAG (25ag/ml) was added 5 min before 
thrombin in these experiments but essentially similar 
results were obtained with 10 s to 10 min pre-incubations 
of vehicle or OAG 
(p < 0.001) less than that obtained in the absence 
of CP/CPK, it was nevertheless significantly 
(p < 0.02) greater than the extent of [14C]5HT 
release obtained with thrombin alone in the pres- 
ence of CP/CPK, which equalled 3.8 f 2%. The 
potentiation of thrombin-induced [14C]5HT secre- 
tion by OAG was significant when OAG was 
added lo-60 s after thrombin or with 10 s to 5 min 
pre-incubations of OAG but became negligible 
with 1Omin pre-incubations of OAG (not shown). 
In platelets not loaded with quin 2 the thrombin 
dose-response curve for [r4C] 5HT secretion was 
shifted approx. 2-fold to the left and potentiatory 
effects of OAG were observed at approx. 2-fold 
lower concentrations of thrombin compared to 
those described in figs 1 and 2. 
At higher thrombin concentrations (>O. 1 U/ml), 
where the rise in [Ca’+] and the extent of [ 14C]5HT 
secretion with thrombin alone were significantly 
higher, OAG added 10 s to 10 min before or 
lo-60 s after thrombin had no significant (p 0.05) 
effect on the rise in [Ca”], or [14C]5HT secretion 
induced by thrombin (results with 5 min OAG pre- 
incubations in table 1). Addition of CP/CPK 
before addition of OAG and thrombin also did not 
affect the thrombin-induced rise in [Ca*+]i or 
[ i4C] 5HT secretion (table 1). 
4. DISCUSSION 
Although earlier workers [9,14,15] using OAG 
have demonstrated a small but significant aggrega- 
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tory and secretory response to OAG, we have been 
unable to demonstrate any significant aggregatory 
or secretory response to OAG in our washed piate- 
let preparations, even in the presence of extracellu- 
lar Ca2+ and fibrinogen. This could be due to the 
absence of released ADP in our final washed plate- 
let suspensions achieved via the use of apyrase in 
our washing procedures, as a recent report [ 161 has 
demonstrated a critical role for ADP in OAG- 
induced 40 kDa phosphorylation and aggregation. 
Interestingly, Lapetina et al. 1131 have demon- 
strated that in platelets isolated in the absence of 
prostacyclin and resuspended in EGTA-free buffer, 
OAG and other active analogues including dihexa- 
noyl- and dioctanylglycerol induced a small aggre- 
gation, but when platelets were isolated in the pres- 
ence of prostacyclin, no aggregation was observed. 
Taking these findings together, it seems likely that 
exogenously added diacylglycerols, which can acti- 
vate protein kinase C in intact platelets, have little 
or no ability to induce aggregation or secretion on 
their own but, as earlier work [16] and the present 
results show, they can synergize strongly with 
other agonists such as ADP and thrombin in 
potentiating aggregation and secretion. Synergism 
between OAG and Ca2+ [8,9,14], which has been 
described earlier with the use of Ca*+ ionophores, 
may account, at least partly, for the synergism 
observed between OAG and low concentrations of 
thrombin, which induced a small but significant 
rise in [Ca”]i. However, it is noteworthy that this 
synergism was also observed in EGTA-treated 
platelets in the absence of a rise in [Ca2+]i, as 
detected using quin 2 methodology, and could be 
mediated via fusogenic effects of OAG facilitating 
secretion [ 191 or could represent an as yet un- 
described mechanism for the potentiation of plate- 
let secretion. Interestingly, aggregation but not 
[r4C]5HT secretion induced by OAG and low con- 
centrations of thrombin was abolished by CPKPK 
indicating that the latter is at least partially inde- 
pendent of released ADP. The role of endogenously 
formed thromboxane A2 in these aggregatory or 
secretory responses can be ruled out as indometha- 
tin, the cyclooxygenase inhibitor, had no signifi- 
cant effect on either phenomenon. 
It is significant that, apart from the potentiatory 
effects described above, OAG had no inhibitory 
effect on thrombin-induced rise in [Ca2+Ji at both 
low and high thrombin concentrations and this 
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represents amajor divergence in the effects of GAG 
and phorbol esters, which have been shown to in- 
hibit agonist-induced [Ca’+]i mobilisation in plate- 
lets [1,2]. Furthermore OAG had no significant 
effect on high-dose thrombin-induced [ y4C] SHT 
secretion and this is at variance with the results of 
Watson and Lapetina [3], who have recently 
demonstrated a significant inhibitory effect of 
OAG on the same. The reasons for this are not 
clear but one possibility is the presence of small 
amounts of prostacyclin because of their platelet 
isolation procedures, and synergistic increases in 
cyclic AMP levels by OAG and prostacyclin [16] 
causing inhibition of platelet activation. It is inter- 
esting however, that these workers 131, who carried 
out pre-incubations of OAG with a single time 
point of lOmin, also failed to demonstrate a 
potentiatory effect of OAG at low thrombin con- 
centrations, as we did with the 10min pre-incuba- 
tions. 
This disappearance of the potentiatory effects of 
OAG on thrombin-induced aggregation and secre- 
tion with pre-incubation times greater than 5 min 
could be due to phosphorylation of OAG into the 
corresponding phosphatidic acid derivative, which 
has been shown to occur within 2min of OAG 
addition to platelets I9,10,21]. However, the pres- 
ence of the potentiatory effects even when OAG 
was added 10-60s after thrombin further em- 
phasises the important role of endogenously formed 
DAG in the amplification of agonist-induced 
platelet responses [8] and, stresses the need for a 
re-examination of the concept that DAG and/or 
protein kinase C may have a specific role in the ter- 
mination of platelet responses. 
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